DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
TOTROMBOPAG
2
Small molecule
Investigational
Unknown
Unknown
Purpura, Thrombocytopenic, Idiopathic
Unknown
TOTROMBOPAG
×
Maximum Phase:
2
First Approval:
None
UNII:
83D6475CAW
Molecule Type:
Small molecule
Molecular Formula:
C25H22N8O2
Molecular Weight:
466.51
AlogP:
4.05
PSA:
131.75
HBD:
3.0
HBA:
#RotB:
5.0
Source:
PRASINEZUMAB
2
Antibody
Investigational
Unknown
Unknown
Parkinson Disease
Alpha-synuclein binding agent
PRASINEZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
P3Z0Z3P1ZI
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CENDERITIDE
2
Protein
Investigational
Unknown
Unknown
ST Elevation Myocardial Infarction; Heart Failure
Unknown
CENDERITIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
9NKZ9LYZ06
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-547
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Cyclin-dependent kinase 1 inhibitor
RG-547
×
Maximum Phase:
2
First Approval:
None
UNII:
T61871RKRI
Molecule Type:
Small molecule
Molecular Formula:
C18H21F2N5O4S
Molecular Weight:
441.46
AlogP:
1.41
PSA:
127.51
HBD:
2.0
HBA:
#RotB:
6.0
Source:
ETHYL PYRUVATE
2
Small molecule
Investigational
Unknown
Unknown
Coronary Disease
Unknown
ETHYL PYRUVATE
×
Maximum Phase:
2
First Approval:
None
UNII:
03O98E01OB
Molecule Type:
Small molecule
Molecular Formula:
C5H8O3
Molecular Weight:
116.12
AlogP:
0.14
PSA:
43.37
HBD:
0.0
HBA:
#RotB:
2.0
Source:
TASIDOTIN HYDROCHLORIDE
2
Protein
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Melanoma; Prostatic Neoplasms, Castration-Resistant
Unknown
TASIDOTIN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
3382C833Z5
Molecule Type:
Protein
Molecular Formula:
C32H59ClN6O5
Molecular Weight:
643.31
AlogP:
2.09
PSA:
122.37
HBD:
2.0
HBA:
#RotB:
11.0
Source:
CBX-129801
2
Unknown
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1; Diabetic Neuropathies
Unknown
CBX-129801
×
Maximum Phase:
2
First Approval:
None
UNII:
IF95YG4W0P
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AROPLATIN
2
Small molecule
Investigational
Unknown
Unknown
Pancreatic Neoplasms; Colorectal Neoplasms
Unknown
AROPLATIN
×
Maximum Phase:
2
First Approval:
None
UNII:
J7M4Z2D183
Molecule Type:
Small molecule
Molecular Formula:
C26H52N2O4Pt
Molecular Weight:
651.79
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
ANCESTIM
2
Protein
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Anemia, Aplastic; Lymphoma; Multiple Myeloma
Unknown
ANCESTIM
×
Maximum Phase:
2
First Approval:
None
UNII:
PYB4Q6JG41
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMVANEX
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
IMVANEX
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LEVOTOFISOPAM
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LEVOTOFISOPAM
×
Maximum Phase:
2
First Approval:
None
UNII:
11ZYL7QK34
Molecule Type:
Small molecule
Molecular Formula:
C22H26N2O4
Molecular Weight:
382.46
AlogP:
4.44
PSA:
61.64
HBD:
0.0
HBA:
#RotB:
6.0
Source:
LULIZUMAB PEGOL
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell-specific surface glycoprotein CD28 antagonist
LULIZUMAB PEGOL
×
Maximum Phase:
2
First Approval:
None
UNII:
LCT264LTYE
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DEUTIVACAFTOR
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Unknown
DEUTIVACAFTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
SHA6U5FJZL
Molecule Type:
Small molecule
Molecular Formula:
C24H28N2O3
Molecular Weight:
401.55
AlogP:
5.08
PSA:
82.19
HBD:
3.0
HBA:
#RotB:
2.0
Source:
FLUOROMISONIDAZOLE
2
Small molecule
Investigational
Unknown
Unknown
Esophageal Neoplasms
Unknown
FLUOROMISONIDAZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
082285VIDF
Molecule Type:
Small molecule
Molecular Formula:
C6H8FN3O3
Molecular Weight:
189.15
AlogP:
0.12
PSA:
81.19
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ADIPIPLON
2
Small molecule
Investigational
Unknown
Unknown
Sleep Initiation and Maintenance Disorders
GABA-A receptor; anion channel partial agonist
ADIPIPLON
×
Maximum Phase:
2
First Approval:
None
UNII:
OPL214POJ1
Molecule Type:
Small molecule
Molecular Formula:
C18H18FN7
Molecular Weight:
351.39
AlogP:
2.83
PSA:
73.79
HBD:
0.0
HBA:
#RotB:
5.0
Source:
ONO-5334
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
ONO-5334
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BALSTILIMAB
2
Antibody
Investigational
Unknown
Unknown
Diffuse Intrinsic Pontine Glioma; Neoplasms; Hemangiosarcoma; Sarcoma; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Programmed cell death protein 1 antagonist
BALSTILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1Q2QT5M7EO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LIFILEUCEL
2
Cell
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Melanoma; Uterine Cervical Neoplasms
Unknown
LIFILEUCEL
×
Maximum Phase:
2
First Approval:
None
UNII:
R0835E18NH
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VONLEROLIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Urinary Bladder Neoplasms
Unknown
VONLEROLIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
C78148TF1D
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
COBOMARSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Mycosis Fungoides
microRNA-155 inhibitor
COBOMARSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
3JKW7CI9IU
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LANDIPIRDINE
2
Small molecule
Investigational
Unknown
Unknown
Parkinson Disease
Unknown
LANDIPIRDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
J0NX985GDI
Molecule Type:
Small molecule
Molecular Formula:
C18H19FN2O3S
Molecular Weight:
362.43
AlogP:
2.75
PSA:
89.26
HBD:
2.0
HBA:
#RotB:
4.0
Source:
POTASSIUM HYDROXIDE
2
Small molecule
Investigational
Unknown
Unknown
Molluscum Contagiosum
Unknown
POTASSIUM HYDROXIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
WZH3C48M4T
Molecule Type:
Small molecule
Molecular Formula:
HKO
Molecular Weight:
56.1
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
CAMPTOTHECIN-20-O-PROPIONATE
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma; Neoplasms; Small Cell Lung Carcinoma
DNA topoisomerase I inhibitor
CAMPTOTHECIN-20-O-PROPIONATE
×
Maximum Phase:
2
First Approval:
None
UNII:
4S145C552U
Molecule Type:
Small molecule
Molecular Formula:
C23H20N2O5
Molecular Weight:
404.42
AlogP:
3.04
PSA:
87.49
HBD:
0.0
HBA:
#RotB:
3.0
Source:
SB-649868
2
Small molecule
Investigational
Unknown
Unknown
Sleep Wake Disorders; Sleep Initiation and Maintenance Disorders
Orexin receptor 1 antagonist
SB-649868
×
Maximum Phase:
2
First Approval:
None
UNII:
1L1V1K2M4V
Molecule Type:
Small molecule
Molecular Formula:
C26H24FN3O3S
Molecular Weight:
477.56
AlogP:
5.43
PSA:
75.44
HBD:
1.0
HBA:
#RotB:
5.0
Source:
TEMELIMAB
2
Antibody
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting
Syncytin-1 inhibitor
TEMELIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
T32CR1A69R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZAMICASTAT
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Pulmonary
Dopamine beta-hydroxylase inhibitor
ZAMICASTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
YLU32D0DNV
Molecule Type:
Small molecule
Molecular Formula:
C21H21F2N3OS
Molecular Weight:
401.48
AlogP:
4.33
PSA:
41.98
HBD:
2.0
HBA:
#RotB:
6.0
Source:
ONC201
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ONC201
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CARBAPENEM
2
Small molecule
Investigational
Unknown
Unknown
Infections
Unknown
CARBAPENEM
×
Maximum Phase:
2
First Approval:
None
UNII:
GL970841YS
Molecule Type:
Small molecule
Molecular Formula:
C7H7NO3
Molecular Weight:
153.14
AlogP:
-0.04
PSA:
57.61
HBD:
1.0
HBA:
#RotB:
1.0
Source:
CARLUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pulmonary Fibrosis
C-C motif chemokine 2 inhibitor
CARLUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
6TC1BB2EV9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OLCEGEPANT
2
Small molecule
Investigational
Unknown
Unknown
Migraine Disorders
Calcitonin gene-related peptide type 1 receptor antagonist
OLCEGEPANT
×
Maximum Phase:
2
First Approval:
None
UNII:
WOA5J8TX6M
Molecule Type:
Small molecule
Molecular Formula:
C38H47Br2N9O5
Molecular Weight:
869.66
AlogP:
4.41
PSA:
176.47
HBD:
5.0
HBA:
#RotB:
12.0
Source:
BGC-20-1531 FREE BASE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BGC-20-1531 FREE BASE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C26H24N2O6S
Molecular Weight:
492.55
AlogP:
4.66
PSA:
107.73
HBD:
1.0
HBA:
#RotB:
8.0
Source:
GSK-2269557
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive
PI3-kinase p110-delta subunit inhibitor
GSK-2269557
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VENGLUSTAT MALATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
VENGLUSTAT MALATE
×
Maximum Phase:
2
First Approval:
None
UNII:
94855LQZ8D
Molecule Type:
Small molecule
Molecular Formula:
C24H30FN3O7S
Molecular Weight:
523.58
AlogP:
4.0
PSA:
54.46
HBD:
1.0
HBA:
#RotB:
4.0
Source:
AZD-5423
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive
Glucocorticoid receptor modulator
AZD-5423
×
Maximum Phase:
2
First Approval:
None
UNII:
641H0Q518W
Molecule Type:
Small molecule
Molecular Formula:
C25H21F4N3O3
Molecular Weight:
487.45
AlogP:
5.36
PSA:
65.38
HBD:
1.0
HBA:
#RotB:
7.0
Source:
EPELSIBAN
2
Small molecule
Investigational
Unknown
Unknown
Adenomyosis
Oxytocin receptor antagonist
EPELSIBAN
×
Maximum Phase:
2
First Approval:
None
UNII:
T2EZ19HX73
Molecule Type:
Small molecule
Molecular Formula:
C30H38N4O4
Molecular Weight:
518.66
AlogP:
2.76
PSA:
91.84
HBD:
1.0
HBA:
#RotB:
6.0
Source:
1
2
…
137
138
139
140
141
142
143
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA